2020 Q2 Form 10-Q Financial Statement

#000156459020037776 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.120M $4.210M
YoY Change -25.89% 69.08%
% of Gross Profit
Research & Development $6.080M $10.46M
YoY Change -41.87% 12.84%
% of Gross Profit
Depreciation & Amortization $220.0K $230.0K
YoY Change -4.35% 50.33%
% of Gross Profit
Operating Expenses $9.260M $22.15M
YoY Change -58.2% 86.06%
Operating Profit -$22.15M
YoY Change 86.07%
Interest Expense -$230.0K $31.00K
YoY Change -841.94% -72.57%
% of Operating Profit
Other Income/Expense, Net $100.0K $215.0K
YoY Change -53.49% -31.31%
Pretax Income -$9.390M -$21.94M
YoY Change -57.2% 89.23%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$9.389M -$21.94M
YoY Change -57.2% 89.24%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$159.5K -$570.8K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $99.60M $111.7M
YoY Change -10.83% 49.33%
Cash & Equivalents $47.10M $16.83M
Short-Term Investments $52.50M $94.90M
Other Short-Term Assets $1.200M $700.0K
YoY Change 71.43% -53.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $102.6M $114.2M
YoY Change -10.13% 47.5%
LONG-TERM ASSETS
Property, Plant & Equipment $800.0K $454.0K
YoY Change 76.21% -35.14%
Goodwill $0.00 $19.43M
YoY Change -100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $700.0K $2.002M
YoY Change -65.03% 66.83%
Total Long-Term Assets $12.50M $33.16M
YoY Change -62.31% -18.12%
TOTAL ASSETS
Total Short-Term Assets $102.6M $114.2M
Total Long-Term Assets $12.50M $33.16M
Total Assets $115.1M $147.3M
YoY Change -21.88% 24.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.000M $4.440M
YoY Change -54.95% 77.6%
Accrued Expenses $4.447M $4.612M
YoY Change -3.58% 64.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $6.500M $9.052M
YoY Change -28.19% 20.69%
LONG-TERM LIABILITIES
Long-Term Debt $24.90M $24.80M
YoY Change 0.4% 89.31%
Other Long-Term Liabilities $0.00 $700.0K
YoY Change -100.0% -94.17%
Total Long-Term Liabilities $24.90M $25.50M
YoY Change -2.35% 1.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.500M $9.052M
Total Long-Term Liabilities $24.90M $25.50M
Total Liabilities $31.30M $34.50M
YoY Change -9.28% -1.99%
SHAREHOLDERS EQUITY
Retained Earnings -$232.7M -$163.8M
YoY Change 42.09% 53.57%
Common Stock $276.4M
YoY Change 46.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $83.80M $112.8M
YoY Change
Total Liabilities & Shareholders Equity $115.1M $147.3M
YoY Change -21.88% 24.92%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$9.389M -$21.94M
YoY Change -57.2% 89.24%
Depreciation, Depletion And Amortization $220.0K $230.0K
YoY Change -4.35% 50.33%
Cash From Operating Activities -$7.750M -$12.90M
YoY Change -39.92% 24.64%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K -$30.00K
YoY Change -33.33% -40.0%
Acquisitions
YoY Change
Other Investing Activities $18.10M -$14.89M
YoY Change -221.56% -225.34%
Cash From Investing Activities $18.09M -$14.92M
YoY Change -221.25% -226.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.330M 19.05M
YoY Change -87.77% 95150.0%
NET CHANGE
Cash From Operating Activities -7.750M -12.90M
Cash From Investing Activities 18.09M -14.92M
Cash From Financing Activities 2.330M 19.05M
Net Change In Cash 12.67M -8.770M
YoY Change -244.47% -684.67%
FREE CASH FLOW
Cash From Operating Activities -$7.750M -$12.90M
Capital Expenditures -$20.00K -$30.00K
Free Cash Flow -$7.730M -$12.87M
YoY Change -39.94% 24.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4211000
CY2019Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
7420000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2020Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2020Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccruedLiabilitiesCurrent
CY2020Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
svra Percentage Of Unpaid Bonus To Be Paid Upon Termination
PercentageOfUnpaidBonusToBePaidUponTermination
1.00
svra Percentage Of Unpaid Bonus To Be Paid Upon Termination
PercentageOfUnpaidBonusToBePaidUponTermination
1.00
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P20M6D
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P20M6D
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
7420000
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
59000
us-gaap Profit Loss
ProfitLoss
-34051000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
206000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
259000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3117000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
583000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
46400000
svra Increase Decrease In Noncurrent Assets
IncreaseDecreaseInNoncurrentAssets
812000
svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
-2376000
svra Increase Decrease In Long Term Liabilities
IncreaseDecreaseInLongTermLiabilities
-467000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20831000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23927000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1862000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-13000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2687000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24301000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47117000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
101698000
CY2020Q1 svra Adjustments To Additional Paid In Capital Closing Costs For Previous Issuance Of Securities In Private Placement
AdjustmentsToAdditionalPaidInCapitalClosingCostsForPreviousIssuanceOfSecuritiesInPrivatePlacement
120000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
28000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1194000
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-128000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
17000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-15421000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
87316000
CY2020Q2 svra Issuance Of Common Stock Upon At The Market Offering Net
IssuanceOfCommonStockUponAtTheMarketOfferingNet
2290000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22154000
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
31000
CY2019Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
110000
CY2019Q2 svra Tax Credit Income
TaxCreditIncome
115000
CY2019Q2 svra Change In Fair Value Of Financial Instruments Net Of Contingent Consideration
ChangeInFairValueOfFinancialInstrumentsNetOfContingentConsideration
-41000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
215000
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21939000
CY2020Q2 svra Stock Issued During Period Value Licensing Of Assets
StockIssuedDuringPeriodValueLicensingOfAssets
2120000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
39000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1175000
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
162000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
85000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-9389000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
455000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
539000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
7420000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5367000
svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
56000
svra Change In Fair Value Of Financial Instruments
ChangeInFairValueOfFinancialInstruments
-118000
svra Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
264000
svra Paid In Kind Interest Income Expense
PaidInKindInterestIncomeExpense
143000
svra Paid In Kind Interest Income Expense
PaidInKindInterestIncomeExpense
-69000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
51000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
292000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
108219000
CY2019Q1 svra Issuance Of Common Stock Upon At The Market Offering Net
IssuanceOfCommonStockUponAtTheMarketOfferingNet
4890000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1000000
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-225000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
26000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-12112000
CY2019Q2 svra Issuance Of Common Stock Upon At The Market Offering Net
IssuanceOfCommonStockUponAtTheMarketOfferingNet
19037000
CY2019Q2 svra Issuance Of Common Stock Upon Settlement Of Contingent Liability
IssuanceOfCommonStockUponSettlementOfContingentLiability
12478000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
61000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1147000
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
91000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
120000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-21939000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
112799000
us-gaap Profit Loss
ProfitLoss
-24811000
svra Accretion On Discount To Short Term Investments
AccretionOnDiscountToShortTermInvestments
113000
svra Accretion On Discount To Short Term Investments
AccretionOnDiscountToShortTermInvestments
688000
us-gaap Share Based Compensation
ShareBasedCompensation
2147000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-115000
svra Increase Decrease In Noncurrent Assets
IncreaseDecreaseInNoncurrentAssets
838000
svra Increase Decrease In Accounts Payable And Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
1141000
svra Increase Decrease In Long Term Liabilities
IncreaseDecreaseInLongTermLiabilities
-103000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23764000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
132000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3247000
svra Payments For Proceeds From Available For Sale Securities Debt
PaymentsForProceedsFromAvailableForSaleSecuritiesDebt
35614000
svra Payments For Proceeds From Available For Sale Securities Debt
PaymentsForProceedsFromAvailableForSaleSecuritiesDebt
92198000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
70600000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8780000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
14129000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16295000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7601000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2290000
us-gaap Repayments Of Debt
RepaymentsOfDebt
514000
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
42000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
86000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
67000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23952000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-58000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7471000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
49804000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16830000
svra Acquisition Of In Process Research And Development
AcquisitionOfInProcessResearchAndDevelopment
-2120000
svra Non Cash Settlement Of Contingent Consideration
NonCashSettlementOfContingentConsideration
12478000
svra Cash Paid For Interest Including End Of Period Charge Due Upon Debt Facility Amendment
CashPaidForInterestIncludingEndOfPeriodChargeDueUponDebtFacilityAmendment
1485000
svra Cash Paid For Interest Including End Of Period Charge Due Upon Debt Facility Amendment
CashPaidForInterestIncludingEndOfPeriodChargeDueUponDebtFacilityAmendment
1058000
svra Number Of Investigational Compounds
NumberOfInvestigationalCompounds
3
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-232700000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20800000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47100000
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
52500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management’s estimates include those related to the accrual of research and development and general and administrative costs, certain financial instruments recorded at fair value, contingent consideration, stock-based compensation, and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Accordingly, actual results could be materially different from those estimates. </p>
svra Liquid Investments Maturity Period
LiquidInvestmentsMaturityPeriod
three months or less
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and foreign exchange derivatives not designated as hedging. The Company places its cash and cash equivalents with a limited number of high-quality financial institutions and at times may exceed the amount of insurance provided on such deposits. </p>
CY2020Q2 us-gaap Goodwill
Goodwill
0
svra In Process Research And Development Increase
InProcessResearchAndDevelopmentIncrease
100000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
svra Date Of Agreement
DateOfAgreement
2018-10-08
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
160274000
CY2020Q2 svra Contingent Milestones Commitments Incurred
ContingentMilestonesCommitmentsIncurred
0
CY2020Q2 svra Contingent Milestones Commitments Remunerated
ContingentMilestonesCommitmentsRemunerated
0
CY2020Q2 svra Contingent Milestones Commitments Accrued
ContingentMilestonesCommitmentsAccrued
0
CY2020Q2 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
1373000
CY2019Q4 svra Prepaid Research And Development Tax Credit Receivable
PrepaidResearchAndDevelopmentTaxCreditReceivable
1253000
CY2020Q2 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
471000
CY2019Q4 svra Prepaid Contracted Research And Development Costs
PrepaidContractedResearchAndDevelopmentCosts
184000
CY2020Q2 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
373000
CY2019Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
364000
CY2020Q2 us-gaap Prepaid Insurance
PrepaidInsurance
530000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
247000
CY2020Q2 svra Foreign Currency Exchange Derivative Current
ForeignCurrencyExchangeDerivativeCurrent
17000
CY2019Q4 svra Foreign Currency Exchange Derivative Current
ForeignCurrencyExchangeDerivativeCurrent
7000
CY2020Q2 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
189000
CY2019Q4 svra Deposits And Other Assets Current
DepositsAndOtherAssetsCurrent
251000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2953000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2306000
CY2020Q2 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
1576000
CY2019Q4 svra Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
2018000
CY2020Q2 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
529000
CY2019Q4 svra Accrued General And Administrative Costs
AccruedGeneralAndAdministrativeCosts
1710000
CY2020Q2 svra Accrued Compensation
AccruedCompensation
1780000
CY2019Q4 svra Accrued Compensation
AccruedCompensation
1303000
CY2020Q2 us-gaap Deferred Revenue
DeferredRevenue
243000
CY2020Q2 svra Accrued Lease Liability
AccruedLeaseLiability
319000
CY2019Q4 svra Accrued Lease Liability
AccruedLeaseLiability
440000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4447000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5471000
CY2020Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
52341000
CY2020Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
151000
CY2020Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
52492000
CY2019Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
71909000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
51000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2019Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
71957000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2020Q2 svra Principal Payments Of Debt And End Of Term Charge Non Current
PrincipalPaymentsOfDebtAndEndOfTermChargeNonCurrent
25162000
CY2020Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
173000
CY2020Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
133000
CY2020Q2 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
24856000
CY2020Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020Q2 svra Common Stock And Preferred Stock Shares Authorized
CommonStockAndPreferredStockSharesAuthorized
201000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52823312
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50790441
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
44381252
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
44544392
CY2017Q1 svra Lease Agreement Date
LeaseAgreementDate
2014-06-19
CY2020Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
39687335
CY2017Q4 svra Lease Commencement Date
LeaseCommencementDate
2018-01-01
CY2017Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-07-31
CY2017Q4 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
200000
svra Lease Commencement Date
LeaseCommencementDate
2018-11-01
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-09-30
us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
100000
CY2020Q2 svra Lease Rental Payments Percentage
LeaseRentalPaymentsPercentage
0.02
CY2017Q1 svra Operating Lease Office Space
OperatingLeaseOfficeSpace
13707
CY2017Q1 svra Lease Commencement Date
LeaseCommencementDate
2017-07-01
CY2017Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-05-31
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
123000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
182000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
67000
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
372000
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
15000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
357000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
299000
us-gaap Operating Lease Cost
OperatingLeaseCost
684000
CY2020Q2 us-gaap Sublease Income
SubleaseIncome
90000
us-gaap Sublease Income
SubleaseIncome
226000
CY2020Q2 us-gaap Lease Cost
LeaseCost
209000
us-gaap Lease Cost
LeaseCost
458000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
200000
us-gaap Operating Lease Payments
OperatingLeasePayments
354000
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
500000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
400000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100000
svra Employment Agreement Description
EmploymentAgreementDescription
Upon termination without cause, and not as a result of death or disability or resignation for good reason, each of such officers is entitled to receive a payment of base salary for twelve months and a pro-rated portion of their unpaid bonus following termination of employment, and such officer will be entitled to continue to receive coverage under medical and dental benefit plans for twelve months or until such officer is covered under a separate plan from another employer. Upon a termination other than for cause or resignation for good reason within twelve months following a change in control, each of such officers is entitled to receive a payment of base salary for eighteen months and one-hundred percent of their unpaid bonus following termination of employment and such officer will be entitled to continue to receive coverage under medical and dental benefit plans for twelve months or until such officer is covered under a separate plan from another employer and will also be entitled to certain acceleration of such officer’s outstanding nonvested options at the time of such termination.
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1175000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1147000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2369000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2147000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37825715
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4294701
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-9389000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-21939000
us-gaap Net Income Loss
NetIncomeLoss
-24811000
us-gaap Net Income Loss
NetIncomeLoss
-34051000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9389000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21939000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24811000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34051000
CY2020Q2 svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-9389000
CY2019Q2 svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-21939000
svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-24811000
svra Undistributed Earnings And Net Income Loss Attributable To Common Stockholders Basic And Diluted
UndistributedEarningsAndNetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
-34051000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58858216
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38440647
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58111225
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37235209
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91

Files In Submission

Name View Source Status
0001564590-20-037776-index-headers.html Edgar Link pending
0001564590-20-037776-index.html Edgar Link pending
0001564590-20-037776.txt Edgar Link pending
0001564590-20-037776-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
svra-10q_20200630.htm Edgar Link pending
svra-10q_20200630_htm.xml Edgar Link completed
svra-20200630.xsd Edgar Link pending
svra-20200630_cal.xml Edgar Link unprocessable
svra-20200630_def.xml Edgar Link unprocessable
svra-20200630_lab.xml Edgar Link unprocessable
svra-20200630_pre.xml Edgar Link unprocessable
svra-ex311_6.htm Edgar Link pending
svra-ex312_8.htm Edgar Link pending
svra-ex321_7.htm Edgar Link pending